Cost-effectiveness of empirical ceftazidime-avibactam for hospital-acquired urinary tract infections: a modeling study identifying key beneficiary subgroups

Background

Hospital-acquired urinary tract infections (HAUTIs) caused by Gram-negative bacilli are increasingly difficult to manage owing to rising carbapenem resistance. The novel antibiotic ceftazidime-avibactam (CAZ-AVI) is a potential alternative, but its cost-effectiveness in this setting is unknown. This study evaluated the cost-effectiveness of empirical CAZ-AVI versus a meropenem-first strategy for treating HAUTIs.